On March 12, 2026 Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), reported the signing of a strategic collaboration agreement on the development and manufacturing of multiple novel bispecific and multispecific antibodies and ADC candidates in Earendil Labs’ pipeline targeting autoimmune disease, cancer, and other diseases.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to accelerate regulatory timelines, enhance CMC execution reliability, and support scalable global clinical development across Earendil Labs’ programs.
WuXi Biologics has built a strong track record in developing complex biologics, particularly its technology strengths in bispecific and multispecific antibodies and ADCs. By 2025, a total of 945 projects were advancing on the company’s integrated CRDMO platform, with bispecific and multispecific antibodies representing one of the fastest‑expanding categories. Leveraging next‑generation technology platforms such as the WuXia TrueSite targeted‑integration CHO cell line platform and the WuXiHigh high‑throughput formulation platform—together with expanded capabilities for high‑dose and subcutaneous delivery, including the Hyaluronidase Co‑Formulation platform and large‑volume device solutions—the company provides development pathways designed to increase efficiency, strengthen product consistency, and enable seamless scale‑up from early research through commercial manufacturing.
Jian Peng, PhD, CEO of Earendil Labs, said: "Partnering with WuXi Biologics enables us to advance our pipeline with greater speed, precision, and CMC excellence. By integrating Earendil Labs’ AI-driven protein‑engineering capabilities with WuXi Biologics’ deep expertise in complex biologics as well as its proven end‑to‑end development and manufacturing capabilities, we can more efficiently advance our pipeline toward clinical milestones to deliver meaningful clinical benefit and transform patient treatment."
Zhenping Zhu, MD, PhD, President & co-CEO of Earendil Labs, added: "Earendil Labs has built a robust and highly competitive pipeline within the past three years. This partnership with WuXi Biologics strengthens our ability to translate AI-driven innovation into high-quality clinical and commercial assets. WuXi Biologics’ proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset therapeutic pipeline for the treatment of various human diseases."
Chris Chen, PhD, CEO of WuXi Biologics, commented, "We are delighted to enter this strategic collaboration with Earendil Labs, a company distinguished by its strong scientific leadership and innovative approach to advancing next‑generation immunotherapies. By leveraging our proven expertise across complex biologics—including bispecific and multispecific antibodies as well as ADCs—and our industry‑leading technology platforms across drug research, development and manufacturing, we aim to accelerate the advancement of Earendil Labs’ innovative pipeline. Through this collaboration, we are poised to accelerate development, ensure robust and scalable manufacturing, and ultimately bring transformative therapies to patients worldwide."
(Press release, Earendil Labs, MAR 12, 2026, View Source [SID1234663515])